A citation-based method for searching scientific literature

Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, Benjamin J Solomon, Gregory J Riely, Myung-Ju Ahn, Caicun Zhou, S Martin Shreeve, Paulina Selaru, Anna Polli, Patrick Schnell, Keith D Wilner, Robin Wiltshire, D Ross Camidge, Lucio Crinò. J Clin Oncol 2015
Times Cited: 409



Sen Zhang, Rana Anjum, Rachel Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats, Yaoyu Ning, Scott D Wardwell, David Miller, Youngchul Song, Lindsey Eichinger, Lauren Moran, Wei-Sheng Huang, Shuangying Liu, Dong Zou, Yihan Wang, Qurish Mohemmad, Hyun Gyung Jang, Emily Ye, Narayana Narasimhan, Frank Wang, Juan Miret, Xiaotian Zhu, Tim Clackson, David Dalgarno, William C Shakespeare, Victor M Rivera. Clin Cancer Res 2016
Times Cited: 163




List of shared articles



Times cited

Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP).
David Heredia, Feliciano Barrón, Andrés F Cardona, Saul Campos, Jerónimo Rodriguez-Cid, Luis Martinez-Barrera, Jorge Alatorre, Miguel Ángel Salinas, Luis Lara-Mejia, Diana Flores-Estrada,[...]. Future Oncol 2021
0


Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.
Elisabeth Smolle, Valentin Taucher, Joerg Lindenmann, Philipp J Jost, Martin Pichler. Cancers (Basel) 2021
2

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Sanjay Popat, Odd Terje Brustugun, Jacques Cadranel, Enriqueta Felip, Marina Chiara Garassino, Frank Griesinger, Åslaug Helland, Maximilian Hochmair, Maurice Pérol, Nawal Bent-Ennakhil,[...]. Lung Cancer 2021
0

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Rudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, Howard L West, Karen L Reckamp, Natasha B Leighl, Marcello Tiseo, Egbert F Smit, Dong-Wan Kim, Scott N Gettinger,[...]. J Thorac Oncol 2020
37

Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.
Anthony V Serritella, Christine M Bestvina. Thorac Surg Clin 2020
4


[Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule].
Yang Wang, Xiaobin Yuan, Jiayan Xiong, Zhidong Hao, Xingzhe Peng, Wanlin Chen, Lingling Cui, Hua Li, Xiulan Wang, Xiangbo He,[...]. Zhongguo Fei Ai Za Zhi 2020
1

Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Takeshi Hirota, Shota Muraki, Ichiro Ieiri. Clin Pharmacokinet 2019
14

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy.
Robert Ali, Junaid Arshad, Sofia Palacio, Raja Mudad. Drug Des Devel Ther 2019
11